Virginia Vanzzini-Zago QFB
Hospital Association to Prevent Blindness, Mexico
Title: A gentle medical treatment for Acanthamoeba keratitis
Submitted Date: 28/06/2017
Biography
Dr. Virginia Vanzzini Zago is currently working as a physician at Hospital Association to Prevent Blindness in Mexico, Mexico, her research interest is in the field of Health Sciences, Medicine ,Ophthalmology, Health Sciences, Immunology.Her dedication and devotion reflects in her vast number of publication at both national and international level.
Abstract
A gentle medical treatment for Acanthamoeba keratitis\r\nAuthors: Virginia Vanzzini-Zago QFB1, Maritza Omaña-Molina PhD, Marino Alcantara-Castro1, Victor Flores-Alvarado1, Dalia Rojo MD1. \r\n1 Hospital Asociación para Evitar la Ceguera en México. Vicente GarcÃa Torres No 46, Coyoacán. CP 03040. México City. 2 Universidad Autónoma de México Plantel Iztacala. México State. \r\nAbstract\r\nIntroduction: Nowadays there is not, a specific and satisfactory treatment for Acanthamoeba keratitis (AK). Aminoglucosides (Neomicin) was de first drug used in the medical AK treatment, imidazoles and tiazols (Itraconazole) associated to debridement are used too for the treatment in the decade of 80. \r\nObjective: The description of a gentle, low cost and available in México, medical treatment for AK in cases with an early diagnosis. \r\nMaterial and Methods: We describe two cases of early clinical and culture proven diagnosed AK, in two young females, in one case with the infection in both corneas (three eyes in total), treated with topic droops of Netilmicin 0.3% (Netira SCIFI Laboratory Italy), two droops each two hours during 48 hours (day and night) and Itraconazole (Nizoral Jenssen laboratory Netherlands) by mouth 200 mgs/24 hs / 15-30 days. After the first 48 hours, the droops of Netilmicin, can be administered 4 times a day, for the time as was needed until the healed cornea was achieved (3 to 4 months). \r\nResults: The 3 Acanthamoeba strains was obtained in cornea scrap cultures, and identified as, A royreba (T4) in case 1 and Acanthamoeba castellanii in case 2. The Acanthamoeba cultures where made in NNA with a layer of live Enterobacter aerogenes. Table No 1 shows the summary of clinical records and evolution.\r\nCase 1 CL\r\nuser Ocular \r\npain Diagnosis Perineural \r\ninfiltrate Stroma\r\n ring Surgery Acantha-\r\nmoeba Healed\r\nFVA\r\nOD + + Superficial AK + No No T4 A\r\nroyreba +\r\n20/20\r\nOS + + Superficial AK + No No T4 A royreba +\r\n20/20\r\nCase 2 + + Cornea ulcer No + No A castelanii + 20/200\r\nDiscussion: In countries where there are not the classic drugs suggested for the treatment of AK, we need to look for others alternatives in the medical treatment. \r\nBibliography: 1. Ishibashi Y, Matsumoto Y. et al Amer Jour Ophthalmol. 1990; 109: 121-126\r\n 2. Lorenzo –Morales J, Khan NA, et al. Parasite. 2015; 22,10 \r\n